Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Go Back to All Clinical Trials

Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Brief description of study

CAPTIVA is a two-stage Phase III trial randomizing subjects with stroke attributed to 70-99% intracranial atherosclerotic stenosis (sICAS) to 12 months treatment of: 1) ticagrelor (180 mg loading dose, then 90mg twice daily) + aspirin 81 mg / day, or 2) low dose rivaroxaban (2.5mg twice daily) + aspirin 81 mg / day, or 3) clopidogrel (600mg loading dose, then 75 mg daily) + aspirin 81 mg/day. The primary goal of the trial is to determine if the experimental arm(s) (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of the primary endpoint (ischemic stroke, intracerebral hemorrhage (ICH), or vascular death).

Clinical Study Identifier: s22-00099

ClinicalTrials.gov Identifier: NCT05047172

Principal Investigator: Brandon Giglio.

Other Investigators: Melissa Jeannie Rethana, Laura Mary Catherine Ades, Aaron S Lord.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies